Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

GCLWW vs CANG vs AUTL vs RERE

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GCLWW
GCL Global Holdings Ltd Warrants

Electronic Gaming & Multimedia

TechnologyNASDAQ • SG
Market Cap$138K
5Y Perf.-67.1%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$250M
5Y Perf.-24.1%
AUTL
Autolus Therapeutics plc

Biotechnology

HealthcareNASDAQ • GB
Market Cap$410M
5Y Perf.-20.8%
RERE
ATRenew Inc.

Specialty Retail

Consumer CyclicalNYSE • CN
Market Cap$1.10B
5Y Perf.+107.8%

GCLWW vs CANG vs AUTL vs RERE — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GCLWW logoGCLWW
CANG logoCANG
AUTL logoAUTL
RERE logoRERE
IndustryElectronic Gaming & MultimediaAuto - DealershipsBiotechnologySpecialty Retail
Market Cap$138K$250M$410M$1.10B
Revenue (TTM)$0.00$3.46B$51M$18.54B
Net Income (TTM)$-1M$-178M$-225M$210M
Gross Margin15.0%13.6%-309.4%20.5%
Operating Margin2.3%7.3%-8.6%1.3%
Forward P/E5.7x1.5x
Total Debt$13M$170M$53M$355M
Cash & Equiv.$18M$1.29B$227M$1.97B

GCLWW vs CANG vs AUTL vs RERELong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GCLWW
CANG
AUTL
RERE
StockFeb 25May 26Return
GCL Global Holdings… (GCLWW)10032.9-67.1%
Cango Inc. (CANG)10075.9-24.1%
Autolus Therapeutic… (AUTL)10079.2-20.8%
ATRenew Inc. (RERE)100207.8+107.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: GCLWW vs CANG vs AUTL vs RERE

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RERE leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. GCL Global Holdings Ltd Warrants is the stronger pick specifically for profitability and margin quality. AUTL also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
GCLWW
GCL Global Holdings Ltd Warrants
The Quality Compounder

GCLWW is the #2 pick in this set and the best alternative if quality is your priority.

  • 3.9% margin vs AUTL's -439.7%
Best for: quality
CANG
Cango Inc.
The Long-Run Compounder

CANG is the clearest fit if your priority is long-term compounding.

  • -44.9% 10Y total return vs GCLWW's -68.7%
Best for: long-term compounding
AUTL
Autolus Therapeutics plc
The Growth Play

AUTL is the clearest fit if your priority is growth exposure.

  • Rev growth 496.0%, EPS growth 27.5%, 3Y rev CAGR 88.7%
  • 496.0% revenue growth vs CANG's -52.7%
Best for: growth exposure
RERE
ATRenew Inc.
The Income Pick

RERE carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 1.36
  • Lower volatility, beta 1.36, Low D/E 9.6%, current ratio 3.19x
  • Beta 1.36, current ratio 3.19x
  • Better valuation composite
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthAUTL logoAUTL496.0% revenue growth vs CANG's -52.7%
ValueRERE logoREREBetter valuation composite
Quality / MarginsGCLWW logoGCLWW3.9% margin vs AUTL's -439.7%
Stability / SafetyRERE logoREREBeta 1.36 vs CANG's 2.25
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)RERE logoRERE+97.4% vs CANG's -73.7%
Efficiency (ROA)RERE logoRERE4.0% ROA vs AUTL's -34.0%, ROIC 1.0% vs -204.1%

GCLWW vs CANG vs AUTL vs RERE — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GCLWWGCL Global Holdings Ltd Warrants
FY 2025
Corporate Segment
99.8%$2M
Other Member
0.2%$4,246
CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M
AUTLAutolus Therapeutics plc
FY 2024
License
100.0%$10M
REREATRenew Inc.
FY 2024
Product
90.9%$14.8B
Service
9.1%$1.5B

GCLWW vs CANG vs AUTL vs RERE — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLRERELAGGINGAUTL

Income & Cash Flow (Last 12 Months)

RERE leads this category, winning 3 of 6 comparable metrics.

RERE and GCLWW operate at a comparable scale, with $18.5B and $0 in trailing revenue. GCLWW is the more profitable business, keeping 3.9% of every revenue dollar as net income compared to AUTL's -4.4%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
RevenueTrailing 12 months$0$3.5B$51M$18.5B
EBITDAEarnings before interest/tax-$771,848$333M-$427M$501M
Net IncomeAfter-tax profit-$1M-$178M-$225M$210M
Free Cash FlowCash after capex-$663,410$0-$278M$0
Gross MarginGross profit ÷ Revenue+15.0%+13.6%-3.1%+20.5%
Operating MarginEBIT ÷ Revenue+2.3%+7.3%-8.6%+1.3%
Net MarginNet income ÷ Revenue+3.9%-5.2%-4.4%+1.1%
FCF MarginFCF ÷ Revenue-7.4%-154.0%-5.4%+3.6%
Rev. Growth (YoY)Latest quarter vs prior year+58.3%+32.2%
EPS Growth (YoY)Latest quarter vs prior year+41.2%+3.6%+3.2%+5.4%
RERE leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

GCLWW leads this category, winning 3 of 4 comparable metrics.

On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than RERE's 16.1x.

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
Market CapShares × price$137,577$250M$410M$1.1B
Enterprise ValueMkt cap + debt − cash-$5M$85M$235M$858M
Trailing P/EPrice ÷ TTM EPS-0.14x5.66x-1.84x-907.40x
Forward P/EPrice ÷ next-FY EPS est.1.46x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple-0.85x3.13x16.11x
Price / SalesMarket cap ÷ Revenue0.00x2.12x40.47x0.46x
Price / BookPrice ÷ Book value/share0.00x0.42x0.96x2.02x
Price / FCFMarket cap ÷ FCF12.79x
GCLWW leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

RERE leads this category, winning 5 of 9 comparable metrics.

RERE delivers a 5.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-85 for AUTL. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to GCLWW's 0.36x. On the Piotroski fundamental quality scale (0–9), RERE scores 7/9 vs CANG's 4/9, reflecting strong financial health.

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
ROE (TTM)Return on equity-9.6%-4.1%-84.7%+5.5%
ROA (TTM)Return on assets-5.6%-2.3%-34.0%+4.0%
ROICReturn on invested capital+8.5%+4.6%-2.0%+1.0%
ROCEReturn on capital employed+9.5%+4.5%-45.9%+0.8%
Piotroski ScoreFundamental quality 0–96457
Debt / EquityFinancial leverage0.36x0.04x0.12x0.10x
Net DebtTotal debt minus cash-$5M-$1.1B-$175M-$1.6B
Cash & Equiv.Liquid assets$18M$1.3B$227M$2.0B
Total DebtShort + long-term debt$13M$170M$53M$355M
Interest CoverageEBIT ÷ Interest expense1.43x-1.87x-25.98x23.67x
RERE leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RERE leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in CANG five years ago would be worth $8,579 today (with dividends reinvested), compared to $2,684 for RERE. Over the past 12 months, RERE leads with a +97.4% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors RERE at 28.8% vs GCLWW's -32.1% — a key indicator of consistent wealth creation.

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
YTD ReturnYear-to-date-16.7%-62.0%-14.2%-14.8%
1-Year ReturnPast 12 months-63.7%-73.7%+30.5%+97.4%
3-Year ReturnCumulative with dividends-68.8%+1.2%-14.6%+113.9%
5-Year ReturnCumulative with dividends-68.7%-14.2%-70.1%-73.2%
10-Year ReturnCumulative with dividends-68.7%-44.9%-93.6%-73.2%
CAGR (3Y)Annualised 3-year return-32.1%+0.4%-5.1%+28.8%
RERE leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — GCLWW and RERE each lead in 1 of 2 comparable metrics.

GCLWW is the less volatile stock with a -1.52 beta — it tends to amplify market swings less than CANG's 2.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RERE currently trades 69.9% from its 52-week high vs GCLWW's 17.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
Beta (5Y)Sensitivity to S&P 500-1.52x2.25x1.95x1.36x
52-Week HighHighest price in past year$0.14$2.88$2.70$6.47
52-Week LowLowest price in past year$0.02$0.33$1.15$2.34
% of 52W HighCurrent price vs 52-week peak+17.5%+18.6%+59.4%+69.9%
RSI (14)Momentum oscillator 0–10043.658.664.339.9
Avg Volume (50D)Average daily shares traded18K1.3M1.6M1.1M
Evenly matched — GCLWW and RERE each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CANG as "Buy", AUTL as "Buy", RERE as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs 452.6% for AUTL (target: $9).

MetricGCLWW logoGCLWWGCL Global Holdin…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…RERE logoREREATRenew Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$3.00$8.87
# AnalystsCovering analysts2142
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises5
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%0.0%+2.5%
Insufficient data to determine a leader in this category.
Key Takeaway

RERE leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GCLWW leads in 1 (Valuation Metrics). 1 tied.

Best OverallATRenew Inc. (RERE)Leads 3 of 6 categories
Loading custom metrics...

GCLWW vs CANG vs AUTL vs RERE: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is GCLWW or CANG or AUTL or RERE a better buy right now?

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — GCLWW or CANG or AUTL or RERE?

Over the past 5 years, Cango Inc.

(CANG) delivered a total return of -14. 2%, compared to -73. 2% for ATRenew Inc. (RERE). Over 10 years, the gap is even starker: CANG returned -44. 9% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — GCLWW or CANG or AUTL or RERE?

By beta (market sensitivity over 5 years), GCL Global Holdings Ltd Warrants (GCLWW) is the lower-risk stock at -1.

52β versus Cango Inc. 's 2. 25β — meaning CANG is approximately -248% more volatile than GCLWW relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 36% for GCL Global Holdings Ltd Warrants — giving it more financial flexibility in a downturn.

04

Which is growing faster — GCLWW or CANG or AUTL or RERE?

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -188. 0% for GCL Global Holdings Ltd Warrants. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — GCLWW or CANG or AUTL or RERE?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — CANG leads at 55. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is GCLWW or CANG or AUTL or RERE more undervalued right now?

Analyst consensus price targets imply the most upside for CANG: 459.

2% to $3. 00.

07

Which pays a better dividend — GCLWW or CANG or AUTL or RERE?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is GCLWW or CANG or AUTL or RERE better for a retirement portfolio?

For long-horizon retirement investors, GCL Global Holdings Ltd Warrants (GCLWW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1.

52)). Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GCLWW: -68. 7%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between GCLWW and CANG and AUTL and RERE?

These companies operate in different sectors (GCLWW (Technology) and CANG (Consumer Cyclical) and AUTL (Healthcare) and RERE (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GCLWW is a small-cap high-growth stock; CANG is a small-cap deep-value stock; AUTL is a small-cap high-growth stock; RERE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

GCLWW

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $20B
  • Revenue Growth > 22%
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Stocks Like

AUTL

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 247%
Run This Screen
Stocks Like

RERE

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 16%
  • Gross Margin > 12%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GCLWW and CANG and AUTL and RERE on the metrics below

Revenue Growth>
%
(GCLWW: 45.7% · CANG: 5833.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.